The coronavirus disease 2019 (COVID-19) outbreak in China was first reported to the World Health Organization on 31 December 2019, after the first cases were officially identified around 8 December 2019. However, the case of an infected patient of 55 years old can probably be traced back on 17 November. The spreading has been rapid and heterogeneous. Economic, political and social impacts have not been long overdue. This paper, based on English, French and Chinese research in national and international databases, aims to study the COVID-19 situation in China through the management of the outbreak and the Chinese response to vaccination strategy. The coronavirus disease pandemic is under control in China through non-pharmaceutical interventions, and the mass vaccination program has been launched to further prevent the disease and progressed steadily with 483.34 million doses having been administered across the country by 21 May 2021. China is also acting as an important player in the development and production of SARS-CoV-2 vaccines.
14 January 2026 in PLOS Neglected Tropical Diseases
The co-administration of albendazole and ivermectin (ALB-IVM) is recommended for the treatment of soil-transmitted helminth (STH) infections, especially where the prevalence of Trichuris trichiura is high. Before large-scale implementation can be considered, feasibility, acceptability and required resources and investments for the mass drug administration (MDA) of ALB-IVM compared with albendazole (ALB) alone should be assessed. This study, conducted in two districts in south-western Uganda, aimed to assess and compare the costs of school-based MDA with ALB-IVM (MDA-ALB-IVM) versus the routinely used ALB alone (MDA-ALB) on a small scale (targeting around 2,500 children per treatment arm per district). We applied a micro-costing (mixed top-down and bottom-up) approach to assess the financial costs from a health system perspective, as well as the opportunity costs of donated ALB. The total (financial and opportunity) costs of MDA-ALB-IVM were higher than those of MDA-ALB ($10,793 for MDA-ALB-IVM versus $4,458 for MDA-ALB in Kabale district and $14,445 versus $5,765 in Kisoro, respectively). The presence of informed consent and assent required for MDA-ALB-IVM (as ALB-IVM is still considered a new therapy for STH infections in Uganda) increased the number of days and resources including personnel requirements for training and drug distribution. Furthermore, adequate community sensitization and the involvement of community health workers (i.e., village health teams in Uganda) and local community leaders appeared to be essential to achieve high treatment coverage. The scenario analysis showed that, in the absence of the informed consent and assent process, the total incremental costs of MDA-ALB-IVM compared with MDA-ALB could decrease by 31%-36% in the two districts. This study identifies key cost drivers and offers insights for the wider implementation of ALB-IVM co-administration.
Introduction Most global health indices or assessment tools focus on health outcomes rather than governance, and they have been developed primarily from the perspective of high-income countries. To benchmark global health governance for equity and solidarity, it becomes necessary to reflect on the current state of indices or assessment tools evaluating health governance across countries. This scoping review aims to review the existing multicountry indices and assessment tools applied globally with measurable indicators assessing health governance; summarise their differences and commonalities; identify the lessons learnt through analysis of their advantages and gaps; and evaluate the feasibility and necessity to establish a new index or consensus framework for assessing global health governance. Methods and analysis This scoping review protocol follows Arksey and O’Malley’s methodological framework, the Joanna Briggs Institute guidelines and the Preferred Reporting Items for Systematic Reviews and Meta-analyses methodology for scoping reviews. Key information sources will be bibliographic databases (PubMed, Embase and Web of Science Core Collection), grey literature and citation tracking. The time frame will be from 1 January 2000 to 31 December 2021. Only indices or assessment tools that are globally applicable and provide measurable indicators of health governance will be eligible. A qualitative content analysis will follow the proposed data extraction form to explicate and compare each eligible index or assessment tool. An analysis based on a proposed preliminary evaluation framework will identify the advantages and gaps and summarise the lessons learnt. This scoping review will also discuss the feasibility and necessity of developing a new global health governance index or consensus framework to inform future research and practices. Ethics and dissemination This scoping review does not require ethics approval. Dissemination will include a peer-review article, policy briefs and conference presentations. This protocol has been registered in the Open Science Framework (osf.io/y93mj).